Project: Novel therapy for intractable tumours bearing oncogenic Kras mutations

This project will employ a novel approach in order to develop a therapeutic agent to combat tumours bearing mutations in a specific gene, in particular Kras mutations, this representing a biomarker that predicts poor disease prognosis. The project will deliver a Novel Chemical Entity (NCE) with proven therapeutic properties against cancer and with a known safety profile.

Acronym TARGETIN’RAS (Reference Number: 10407)
Duration 01/09/2016 - 01/03/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
23968 Allinky Biopharma SL Coordinator Spain
23969 Sequani Limited Partner United Kingdom
23970 Crelux GmbH Partner Germany